Drug Trial Radar · NCT07622186
A Study of SKB571 Combination Therapy in Participants With Non-Small Cell Lung Cancer (NSCLC)
Last checked: Nov 19, 2026Latest source record: Sep 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
150
Planned (sponsor's estimate)
Start
Jul 15, 2026
Primary completion
Dec 31, 2028
Study completion Dec 31, 2029
Sponsor
- Lead sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 3, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, multicenter, phase II study. The purpose of this study is to evaluate the safety, tolerability and preliminary anti-tumor activity of SKB571 Combination Therapy in participants with Non-Small Cell Lung Cancer (NSCLC).
Conditions
- Non-Small Cell Lung Cancer
Interventions
SKB571 for injectionDrug
Intravenous(IV) infusion(Q3W)
OsimertinibDrug
orally once daily
FurmonertinibDrug
orally once daily
carboplatinDrug
Intravenous(IV) infusion(Q3W)
CisplatinDrug
Intravenous(IV) infusion(Q3W)
PembrolizumabDrug
Intravenous(IV) infusion(Q3W)
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective response rate (ORR)Time frame: Up to approximately 36 months
Locations
27 sites in 1 country. Site status is shown where the registry gives one.
Peking University Cancer Hospital
Beijing, Beijing Municipality, China · Not yet recruiting
Xinqiao Hospital of Army Medical University
Chongqing, Chongqing Municipality, China · Not yet recruiting
Fujian Provincial Cancer Hospital
Fuzhou, Fujian, China · Not yet recruiting
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China · Not yet recruiting
Dongguan People's Hospital
Dongguan, Guangdong, China · Not yet recruiting
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, China · Recruiting
Guangzhou Medical University First Affiliated Hospital
Guangzhou, Guangdong, China · Recruiting
Guilin Medical University First Affiliated Hospital
Guilin, Guangxi, China · Not yet recruiting
Guangxi Medical University Affiliated Tumor Hospital
Nanning, Guangxi, China · Not yet recruiting
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China · Not yet recruiting
Henan Cancer Hospital
Zhengzhou, Henan, China · Not yet recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China · Not yet recruiting
Xiangyang Central Hospital
Xiangyang, Hubei, China · Not yet recruiting
Hunan Cancer Hospital
Changsha, Hunan, China · Not yet recruiting
Jiangsu Province Hospital
Nanjing, Jiangsu, China · Not yet recruiting
Jiangxi Cancer Hospital
Nanchang, Jiangxi, China · Not yet recruiting
Jilin Cancer Hospital
Changchun, Jilin, China · Not yet recruiting
Shengjing Hospital of China Medical University
Shenyang, Liaoning, China · Not yet recruiting
Shandong Cancer Hospital
Jinan, Shandong, China · Not yet recruiting
Shanxi Cancer Hospital
Taiyuan, Shanxi, China · Not yet recruiting
The First Affiliated Hospital of Xi'an Jiao Tong University
Xi’an, Shanxi, China · Not yet recruiting
Sichuan Cancer Hospital & Institute
Chengdu, Sichuan, China · Not yet recruiting
West China Hospital, Sichuan University
Chengdu, Sichuan, China · Not yet recruiting
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China · Not yet recruiting
Xinjiang Medical University Affiliated Tumor Hospital
Ürümqi, Xinjiang Uygur Autonomous Region, China · Not yet recruiting
Yunnan Cancer Hospital
Kunming, Yunnan, China · Not yet recruiting
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China · Not yet recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.